Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278515 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL277967 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1896226 | 0.92 | PPM1D (0.35) | PPM1D | |
| SCHEMBL16516673 | 0.89 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1015667 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL18535817 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL360950 | 0.88 | PPM1D (0.36) | PPM1D | |
| SCHEMBL661089 | 0.88 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-116648248-B | Aromatic compound, pharmaceutical composition containing same and application thereof | 成都茵创园医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025049254-A1 | PYRAZOLOPYRIDINE BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-5622970-A | CONTROLLING GRAFT REJECTION | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620971-A | Biologically active acylated amino acid derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-04-15 | — | — | US | disclosed |
| US-5516797-A | SUPPRESSING GRAFT REJECTION | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-05-14 | — | — | US | disclosed |
| US-5330993-A | Immunosuppressive compounds | VERTEX PHARMACEUTICALS, INC. (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1994007858-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0584223-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0537269-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS. | VERTEX PHARMA (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5192773-A | Isomerase inhibitor | VERTEX PHARMACEUTICALS, INC. (US) | 1993-03-09 | — | — | US | disclosed |
| WO-1992019593-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992000278-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PPM1D 976/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PPM1D 524/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | PPM1D 879/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | PPM1D 524/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | PPM1D 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.